Overview

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Etanercept
Tofacitinib